RSS   Newsletter   Contact   Advertise with us
Post Online Media

Advanced Oncotherapy appoints two non-executive directors

Advanced OncotherapyAdvanced Oncotherapy, a developer of medical technology for cancer treatment, announced the appointment of Steve Myers OBE and Hans von Celsing as non-executive directors.
Professor Myers has been part of the Advanced Oncotherapy Leadership Team since his appointment as Executive Chairman of the Company's fully owned subsidiary ADAM S.A., in November 2015.

Before joining Advanced Oncotherapy, Professor Myers was Head of Medical Applications at CERN in Geneva and before that, was Director of Accelerators and Technology at CERN.

There, he was responsible for the operation and exploitation of the whole accelerator complex, with particular emphasis on the Large Hadron Collider (LHC) and the development of new projects and technologies.

He is a Fellow of the Royal Academy of Engineering, the Institute of Physics, the European Physical Society and International Fellow of the American Physical Society.

Professor Myers is internationally recognised for his engineering contributions and leadership in the development of CERN's particle colliders over the past 40 years, including the Intersecting Storage Ring Accelerator, the Large Electron-Positron collider and the LHC.

Professor Myers has been awarded a number of international prizes including the EPS Edison Volta Prize and the Prince of Asturias Prize of Spain. He was awarded an OBE in 2013 for services to science and technology.

Professor Myers holds a number of honorary degrees and advisory positions and is Chair of the Advisory Committees of both the John Adams Accelerator Institute in Oxford and the Cockcroft Accelerator Institute. He has published over 300 scientific papers.

Mr. von Celsing will become Senior Independent Non-Executive Director. He was an Adviser to Mevion Medical Systems for eight years and supported their international expansion in Europe and Asia.

Mr von Celsing also joined Elekta, a Swedish medical technology group, as Executive Vice President, in its early stages in 1985.

Mr. von Celsing has held a number of Board level roles throughout his career, and has particular expertise in the areas of life sciences, medical devices and diagnostics.

He is currently Chairman of Clinical Laser Thermia Systems, a public quoted medical technology company in Lund, Sweden.

He is also Chairman of Gelexir Healthcare Ltd, a medical technology company based in Manchester, Chairman of Partner Fondkommission, an independent investment banking company based in Gothenburg, Sweden, and Chairman of Peptonic Medical, a publicly quoted biopharmaceutical company in Stockholm.


 LATEST MOVES FROM United Kingdom 


POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.